{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:29:40Z","timestamp":1783582180363,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-036437"],"award-info":[{"award-number":["INV-036437"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/07"],"award-info":[{"award-number":["MC_UU_00004\/07"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/09"],"award-info":[{"award-number":["MC_UU_00004\/09"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/09"],"award-info":[{"award-number":["MC_UU_00004\/09"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Typhoid fever causes nearly 110,000 deaths among 9.24 million cases globally and disproportionately affects developing countries. As a control measure in such regions, typhoid conjugate vaccines (TCVs) are recommended by the World Health Organization (WHO). We present here the protocol of a cluster randomised vaccine trial to assess the impact of introducing TyphiBEV\u00ae vaccine to those between 1 and 30\u00a0years of age in a high-burden setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The primary objective is to determine the relative and absolute rate reduction of symptomatic, blood-culture-confirmed <jats:italic>S.<\/jats:italic> Typhi infection among participants vaccinated with TyphiBEV\u00ae in vaccine clusters compared with the unvaccinated participants in non-vaccine clusters. The study population is residents of 30 wards of Vellore (a South Indian city) with participants between the ages of 1 and 30\u00a0years who provide informed consent. The wards will be divided into 60 contiguous clusters and 30 will be randomly selected for its participants to receive TyphiBEV\u00ae at the start of the study. No placebo\/control is planned for the non-intervention clusters, which will receive the vaccine at the end of the trial. Participants will not be blinded to their intervention. Episodes of typhoid fever among participants will be captured via stimulated, passive fever surveillance in the area for 2\u00a0years after vaccination, which will include the most utilised healthcare facilities. Observers blinded to the participants\u2019 intervention statuses will record illness details. Relative and absolute rate reductions will be calculated at the end of this surveillance and used to estimate vaccine effectiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The results from our trial will allow countries to make better-informed decisions regarding the TCV that they will roll-out and may improve the global supplies and affordability of the vaccines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical Trials Registry of India (CTRI) CTRI\/2022\/03\/041314. Prospectively registered on 23 March 2022 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=62548&amp;EncHid=&amp;userName=vellore%20typhoid\">https:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=62548&amp;EncHid=&amp;userName=vellore%20typhoid<\/jats:ext-link>). CTRI collects the full WHO Trial Registration Data Set.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07555-y","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T04:01:32Z","timestamp":1691035292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An observer-blinded, cluster randomised trial of a typhoid conjugate vaccine in an urban South Indian cohort"],"prefix":"10.1186","volume":"24","author":[{"given":"Nikhil","family":"Sahai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilesh Kumar","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Copas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Raghava","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Anish","family":"Selwyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winsley","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeraraghavan","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3654-5099","authenticated-orcid":false,"given":"Jacob","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"7555_CR1","unstructured":"The Institute for Health Metrics and Evaluation. https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/typhoid-and-paratyphoid-level-3-cause. Accessed 3 Feb 2023."},{"key":"7555_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","volume":"19","author":"JD Stanaway","year":"2019","unstructured":"Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19:369\u201381.","journal-title":"Lancet Infect Dis"},{"key":"7555_CR3","doi-asserted-by":"publisher","first-page":"e978","DOI":"10.1016\/S2214-109X(22)00119-X","volume":"10","author":"DO Garrett","year":"2022","unstructured":"Garrett DO, Longley AT, Aiemjoy K, Yousafzai MT, Hemlock C, Yu AT, et al. Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project. Lancet Glob Heal. 2022;10:e978\u201388.","journal-title":"Lancet Glob Heal"},{"key":"7555_CR4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2209449","volume":"388","author":"J John","year":"2023","unstructured":"John J, Bavdekar A, Rongsen-Chandola T, Dutta S, Gupta M, Kanungo S, et al. Burden of typhoid and paratyphoid fever in India. N Engl J Med. 2023;388:1491\u2013500.","journal-title":"N Engl J Med"},{"key":"7555_CR5","doi-asserted-by":"publisher","first-page":"794868","DOI":"10.3389\/fpubh.2021.794868","volume":"9","author":"MH Butt","year":"2021","unstructured":"Butt MH, Saleem A, Javed SO, Ullah I, Rehman MU, Islam N, et al. Rising XDR-typhoid fever cases in Pakistan: are we heading back to the pre-antibiotic era? Front Public Heal. 2021;9:794868.","journal-title":"Front Public Heal"},{"key":"7555_CR6","doi-asserted-by":"publisher","first-page":"S781","DOI":"10.1093\/infdis\/jiab449","volume":"224","author":"M Birkhold","year":"2021","unstructured":"Birkhold M, Mwisongo A, Pollard AJ, Neuzil KM. Typhoid conjugate vaccines: advancing the research and public health agendas. J Infect Dis. 2021;224:S781\u20137.","journal-title":"J Infect Dis"},{"issue":"5","key":"7555_CR7","doi-asserted-by":"publisher","first-page":"2043103","DOI":"10.1080\/21645515.2022.2043103","volume":"18","author":"S Thuluva","year":"2022","unstructured":"Thuluva S, Paradkar V, Matur R, Turaga K, Gv SR. A multicenter, single-blind, randomized, phase-2\/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E\u2019s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator. Hum Vaccin Immunother. 2022;18(5):2043103.","journal-title":"Hum Vaccin Immunother"},{"key":"7555_CR8","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1093\/infdis\/jiab150","volume":"224","author":"T Ryckman","year":"2021","unstructured":"Ryckman T, Karthikeyan AS, Kumar D, Cao Y, Kang G, Goldhaber-Fiebert JD, et al. Comparison of strategies for typhoid conjugate vaccine introduction in India: a cost-effectiveness modeling study. J Infect Dis. 2021;224:S612\u201324.","journal-title":"J Infect Dis"},{"key":"7555_CR9","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1016\/j.vaccine.2021.06.003","volume":"39","author":"AS Chauhan","year":"2021","unstructured":"Chauhan AS, Kapoor I, Rana SK, Kumar D, Gupta M, John J, et al. Cost effectiveness of typhoid vaccination in India. Vaccine. 2021;39:4089.","journal-title":"Vaccine"},{"key":"7555_CR10","first-page":"346","volume":"2013","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, SPIRIT, et al. explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;2013:346.","journal-title":"BMJ"},{"key":"7555_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.4269\/ajtmh.18-0232","volume":"99","author":"MV Murhekar","year":"2018","unstructured":"Murhekar MV, Ashok M, Kanagasabai K, Joshua V, Ravi M, Sabarinathan R, et al. Epidemiology of hepatitis A and hepatitis E based on laboratory surveillance data\u2014India, 2014\u20132017. Am J Trop Med Hyg. 2018;99:1058.","journal-title":"Am J Trop Med Hyg"},{"key":"7555_CR12","unstructured":"Government of Tamil Nadu Health and Family Welfare Department. https:\/\/tnhealth.tn.gov.in\/tngovin\/dph\/dphdbje.php. Accessed 21 Mar 2023."},{"key":"7555_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-022-06097-z","volume":"23","author":"TP Morris","year":"2022","unstructured":"Morris TP, Walker AS, Williamson EJ, White IR. Planning a method for covariate adjustment in individually randomised trials: a practical guide. Trials. 2022;23:1\u201317.","journal-title":"Trials"},{"key":"7555_CR14","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"key":"7555_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07555-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07555-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07555-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T04:02:00Z","timestamp":1691035320000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07555-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7555"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07555-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study proposal was reviewed and approved by India\u2019s Health Ministry Screening Committee (proposal ID 2022\u201316229, dated 16 March 2022). The protocol was approved by the IRB of CMC Vellore (IRB minutes number 14247, dated 29\/09\/2021). Any changes or amendments made to the protocol will be submitted to the IRB for approval.Written informed consent will be taken from all adult participants and from the parents of child participants with assent being sought wherever applicable. This will include consent for study staff to review participants\u2019 medical and diagnostic records and store any additional serum samples for future research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable\u2014no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"492"}}